Samarth Kulkarni - 20 Mar 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CRSP
Reported as of: 20 Mar 2026
Net transaction value: -$468,736
SEC form: 4
Accepted by SEC: 24 Mar 2026, 17:37:54 UTC
Prior SEC filing: 17 Mar 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Samarth Kulkarni filed Form 4 for CRISPR Therapeutics AG (CRSP) on 24 Mar 2026.

Key facts

This page summarizes Samarth Kulkarni's Form 4 filing for CRISPR Therapeutics AG (CRSP).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Mar 2026, 17:37.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: -$468,736.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001682019 Primary reporting owner

Kulkarni Samarth

Relationship: Chief Executive Officer, Director
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 24 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP transaction

Common Shares

Options Exercise

Transaction value
Shares: +19,687
Change %: +8%
Price
Shares after: 265,521
Date: 20 Mar 2026
Ownership: Direct
Footnotes: F1, F2

CRSP transaction

Common Shares

Sale

Transaction value: $468,736
Shares: -10,020
Change %: -3.8%
Price: $46.78
Shares after: 255,501
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +114,249
Change %
Price: $0.000000^*
Shares after: 114,249
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 114,249
Exercise price: $46.24
Footnotes: F1, F4

CRSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +81,875
Change %
Price: $0.000000^*
Shares after: 81,875
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 81,875
Exercise price
Footnotes: F1, F5

CRSP transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -19,687
Change %: -33%
Price
Shares after: 39,375
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 19,687
Exercise price
Footnotes: F1, F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F3

Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Footnote F4

This option was granted on March 20, 2026 with respect to 114,249 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

Footnote F5

This restricted stock unit award was granted on March 20, 2026 with respect to 81,875 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

Footnote F6

This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.